Qianyuan Pharmaceuticals (300254.SZ): Won the 20% equity stake in Qianyuan Hailisheng at a price of 77.36 million yuan

NightAirdropper · 2026-02-28T09:14:01+00:00

Qianyuan Pharmaceuticals will auction 40% of its subsidiary Qianyuan Hailisheng in 2026, with an estimated value of nearly 177 million yuan. The company successfully bid jointly with Zhoushan Ronghao, acquiring a 20% stake for approximately 154 million yuan. This move will help enhance the company's profitability and competitiveness.

NightAirdropper

2026-02-28 09:14:01

Abstract generation in progress

Qian Yuan Medicine (300254.SZ) announced that according to the notice from the Ningbo Yinzhou District People’s Court in Zhejiang Province, a public auction will be held on the Taobao Judicial Auction Platform from 10:00 AM on February 24, 2026, to 10:00 AM on February 25, 2026 (excluding extensions). The auction will be for a 40% stake in Qian Yuan Haili Sheng. The appraised value of the auction target is 177.303197 million yuan, with a starting bid of 124.12 million yuan, a deposit of 20 million yuan, and an incremental bid of 600,000 yuan. On February 25, 2026, based on the public notice from the Ningbo Yinzhou District People’s Court on the Taobao Judicial Auction Platform, the company and Zhoushan Ronghao jointly bid 154.72 million yuan to acquire the 40% equity stake in Haili Sheng Group Co., Ltd. held by Qian Yuan Haili Sheng. The company will pay the remaining transaction amount and complete relevant business registration procedures as required.

Qian Yuan Haili Sheng is a major subsidiary of the company. Participating in the auction of a 20% stake in Qian Yuan Haili Sheng can bring continuous and stable investment income and net profit contribution to the company, further enhancing the company’s overall operating performance and profitability, and strengthening its sustainable development capability and comprehensive competitiveness.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.